Cardiotoxicity Market to Witness Growth by 2032, Estimates DelveInsight | Terumo Cardiovascular Systems Corporation., Medtronic, Boston Scientific Corporation, Biotronik, Liva Nova, CR Bard, Abbott

May 25 19:00 2023
Cardiotoxicity Market to Witness Growth by 2032, Estimates DelveInsight | Terumo Cardiovascular Systems Corporation., Medtronic, Boston Scientific Corporation, Biotronik, Liva Nova, CR Bard, Abbott
Cardiotoxicity Market

(New York, USA) DelveInsight’s “Cardiotoxicity Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Cardiotoxicity, historical and forecasted epidemiology as well as the Cardiotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Cardiotoxicity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cardiotoxicity market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Cardiotoxicity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cardiotoxicity market.

 

Request for a Free Sample Report @ Cardiotoxicity Market Forecast

 

Some facts of the Cardiotoxicity Market Report are:

  • According to DelveInsight, Cardiotoxicity market size is expected to grow at a decent CAGR by 2032.
  • Leading Cardiotoxicity companies working in the market are Terumo Cardiovascular Systems Corporation., Medtronic, Boston Scientific Corporation, Biotronik, Liva Nova, CR Bard, Becton Dickson Company, Cardinal Health Inc., Abbott, Johnson & Johnson Services, Inc., Cook Medical, and others.
  • Key Cardiotoxicity Therapies expected to launch in the market are Annamycin, Camsirubicin and others.
  • Cardiotoxicity was found in 39.6% of anthracycline-treated patients in a recent study (Sendon et al., 2020).
  • Cardiotoxicity also seen in patients who were taking anti-HER2 (43.5%), anthracycline and anti-HER2 (45.7%), TKI (50%), left breast radiotherapy (44.8%), and mediastinal radiotherapy (29.1%). (Sendon et al., 2020).
  • Around one-third of cancer patients who receive chemotherapy drugs including trastuzumab (Herceptin) and anthracyclines have heart cell damage (University of Michigan, n.d.).

 

Cardiotoxicity Overview

Cardiotoxicity refers to the potential harmful effects of certain substances or treatments on the heart. It is characterized by damage or dysfunction of the heart muscle (cardiomyopathy) or disturbances in the electrical conduction system of the heart (arrhythmias). Cardiotoxicity can occur as a side effect of various medications, chemotherapy drugs, radiation therapy, or other environmental factors.

Certain medications, particularly those used to treat cancer, can have cardiotoxic effects. These include certain chemotherapy drugs (e.g., anthracyclines such as doxorubicin), targeted therapies (e.g., trastuzumab), and some antimicrobial agents (e.g., certain antibiotics and antifungals). These medications can directly damage the heart muscle cells, leading to impaired heart function. The risk and severity of cardiotoxicity depend on factors such as the specific medication, cumulative dose, patient’s age, pre-existing heart conditions, and other individual factors.

 

Learn more about Cardiotoxicity treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market

 

Cardiotoxicity Market 

The Cardiotoxicity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Cardiotoxicity market trends by analyzing the impact of current Cardiotoxicity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Cardiotoxicity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cardiotoxicity market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cardiotoxicity market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Cardiotoxicity Epidemiology

The Cardiotoxicity epidemiology section provides insights into the historical and current Cardiotoxicity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Cardiotoxicity market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Cardiotoxicity Epidemiology @ https://www.delveinsight.com/sample-request/cardiotoxicity-market

 

Cardiotoxicity Drugs Uptake

This section focuses on the uptake rate of the potential Cardiotoxicity drugs recently launched in the Cardiotoxicity market or expected to be launched in 2019-2032. The analysis covers the Cardiotoxicity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Cardiotoxicity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Cardiotoxicity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Cardiotoxicity Pipeline Development Activities

The Cardiotoxicity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Cardiotoxicity key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Cardiotoxicity pipeline development activities @ https://www.delveinsight.com/sample-request/cardiotoxicity-market

 

Cardiotoxicity Therapeutics Assessment

Major key companies are working proactively in the Cardiotoxicity Therapeutics market to develop novel therapies which will drive the Cardiotoxicity treatment markets in the upcoming years are Terumo Cardiovascular Systems Corporation., Medtronic, Boston Scientific Corporation, Biotronik, Liva Nova, CR Bard, Becton Dickson Company, Cardinal Health Inc., Abbott, Johnson & Johnson Services, Inc., Cook Medical, and others.

 

Learn more about the emerging Cardiotoxicity therapies & key companies @ https://www.delveinsight.com/sample-request/cardiotoxicity-market

 

Cardiotoxicity Report Key Insights

1. Cardiotoxicity Patient Population

2. Cardiotoxicity Market Size and Trends

3. Key Cross Competition in the Cardiotoxicity Market

4. Cardiotoxicity Market Dynamics (Key Drivers and Barriers)

5. Cardiotoxicity Market Opportunities

6. Cardiotoxicity Therapeutic Approaches

7. Cardiotoxicity Pipeline Analysis

8. Cardiotoxicity Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Cardiotoxicity Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Cardiotoxicity Competitive Intelligence Analysis

4. Cardiotoxicity Market Overview at a Glance

5. Cardiotoxicity Disease Background and Overview

6. Cardiotoxicity Patient Journey

7. Cardiotoxicity Epidemiology and Patient Population

8. Cardiotoxicity Treatment Algorithm, Current Treatment, and Medical Practices

9. Cardiotoxicity Unmet Needs

10. Key Endpoints of Cardiotoxicity Treatment

11. Cardiotoxicity Marketed Products

12. Cardiotoxicity Emerging Therapies

13. Cardiotoxicity Seven Major Market Analysis

14. Attribute Analysis

15. Cardiotoxicity Market Outlook (7 major markets)

16. Cardiotoxicity Access and Reimbursement Overview

17. KOL Views on the Cardiotoxicity Market

18. Cardiotoxicity Market Drivers

19. Cardiotoxicity Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services